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(Trans)-3,7-Dimethyl-2,6-octadien-1-ol, commonly called geraniol (Ge-OH), is an acyclic
monoterpene alcohol with well-known anti-inflammatory, antitumoral, and antimicrobial
properties. It is widely used as a preservative in the food industry and as an antimicrobial
agent in animal farming. The present study investigated the role of Ge-OH as an
anti-inflammatory and anti-dysbiotic agent in the dextran sulfate sodium (DSS)-induced
colitis mouse model. Ge-OH was orally administered to C57BL/6 mice at daily doses of
30 and 120mg kg(−1) body weight, starting 6 days before DSS treatment and ending
the day after DSS removal. Furthermore, Ge-OH 120mg kg(−1) dose body weight was
administered via enema during the acute phase of colitis to facilitate its on-site action. The
results show that orally or enema-administered Ge-OH is a powerful antimicrobial agent
able to prevent colitis-associated dysbiosis and decrease the inflammatory systemic
profile of colitic mice. As a whole, Ge-OH strongly improved the clinical signs of colitis
and significantly reduced cyclooxygenase-2 (COX-2) expression in colonocytes and in
the gut wall. Ge-OH could be a powerful drug for the treatment of intestinal inflammation
and dysbiosis.
Keywords: geraniol, inflammatory bowel disease (IBD), dextran sulfate sodium (DSS)-induced colitis,
cyclooxygenase-2 (COX-2), inflammation, dysbiosis
INTRODUCTION
More than 90% of the 100 trillion cells in the human body are microbes, most of which reside
in the digestive tract and are collectively known as the intestinal microbiota (Yaung et al., 2014).
The bacterial flora is extremely dense and diverse and shapes fundamental physiological processes
such as digestion and the development of gut-associated lymphoid tissues and systemic immunity.
The intestinal microbiota plays a crucial role in maintaining colonic homeostasis, while microbial
dysbiosis can contribute to a wide spectrum of disease (Kamada et al., 2013).
Abbreviations:Ge-OH, geraniol; DSS, Dextran sulfate sodium; IBD, Inflammatory bowel disease; COX-2, Cyclooxygenase-2;
CRC, Colorectal cancer.
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Inflammatory bowel disease (IBD), which includes Crohn’s
disease (CD), and ulcerative colitis (UC), is a chronic
inflammatory disorder of the intestinal tract associated with
abdominal pain, intestinal bleeding, weight loss, and diarrhea
(Koloski et al., 2008). The etiology of IBD is unknown but the
one dominant hypothesis is that the inflammation results from
altered or pathogenic microbiota in a genetically susceptible
host. A growing body of literature implicates the abnormal
overgrowth or dominance of particular bacterial species in the
pathogenesis of IBD. Notably, mouse model studies of IBD
have shown protection against the development of IBD in a
germ-free environment, corroborating the role of gut flora in
the pathogenesis of this spectrum of illnesses (Missaghi et al.,
2014).
As in humans, the two most abundant bacterial phyla in
C57BL6/J mice are the Firmicutes (60–80% of sequences) and
the Bacteroidetes (20–40%). Few bacteria are present in the
mouse gut soon after birth. The neonate is inoculated with
microorganisms by the mother and the environment and the
microbiota is fully established when themouse reaches adulthood
at around 8 weeks, even if it is still susceptible to changes in
composition (Laukens et al., 2015). In healthy adults, diet changes
remain the major player in microbiota dynamics.
Essential oil mixtures have been shown to play a significant
role in the modulation of animal gut microbiota (Oviedo-
Rondón et al., 2006) but their mechanism(s) of action remain
incompletely understood (Thompson et al., 2013).
Essential oils (EO) are volatile natural complex compounds
characterized by a strong odor and synthesized by aromatic
plants as secondary metabolites (Bakkali et al., 2008). They are
highly complex natural mixtures which may contain up to 60
components at widely varying concentrations. In nature, EO play
important roles in the protection of plants acting as antibacterial,
antiviral, antifungal, and insecticidal agents (Bakkali et al., 2008;
Fang et al., 2010). Recently, EO have been used in animal feed
to treat infections, manipulate gut fermentation, and improve
productivity (Wallace et al., 2010).
Geraniol (Ge-OH) is a naturally acyclic monoterpene
component of EO extracted from lemongrass, rose, and other
aromatic plants. Several studies on the biological activities of Ge-
OH have shown it to be a highly active antitumoral, antimicrobial
compound, with antioxidant and anti-inflammatory properties
(Ahmad et al., 2011; Thapa et al., 2012; Khan et al., 2013).
Ge-OH’s antimicrobial activities do not seem to have specific
cellular targets. Like other EO, Ge-OH is a hydrophobic
compound able to bind to the bacterial wall modifying its
dynamic organization, with a consequent loss of ions and
ATP depletion (Di Pasqua et al., 2006; Turina et al., 2006).
In addition to bacterial growth inhibition, especially effective
on Gram-positive bacteria (Thapa et al., 2012), Ge-OH also
damages bacterial proteins, and lipids (Burt, 2004; Oussalah
et al., 2007). Ge-OH effectively modulates the drug resistance of
several Gram-negative bacterial species such as E. aerogenes, E.
coli, and P. aeruginosa by restoring drug susceptibility in strains
overexpressing eﬄux pumps (Solórzano-Santos and Miranda-
Novales, 2012). It is important to emphasize that human
pathogenic bacteria are more sensitive to Ge-OH than are
commensal species even if the nature of this selectivity remains
unsettled (Singh et al., 2012).
Ge-OH has antioxidant activities in eukaryotic cells (Khan
et al., 2013). By reducing oxidative stress, Ge-OH may prevent
drug-induced mitochondrial dysfunction in hepatocytes (Singh
et al., 2012). In vivo, it proved able to enhance neurodegeneration
in a mice model of Parkinson’s disease (Rekha et al., 2013).
In vitro and in vivo, Ge-OH inhibits the expression of
cyclooxygenase-2 (COX-2; Chaudhary et al., 2013), a key enzyme
in inflammation (Strillacci et al., 2010). The anti-inflammatory
properties of Ge-OH have been assessed on different animal
models and in this context it has been shown that its molecular
target is not only COX-2 but also NF-kB (Marcuzzi et al., 2011;
Khan et al., 2013; Medicherla et al., 2015).
Considering all its activities, Ge-OH seems to be an excellent
candidate for the treatment of gut and systemic inflammations
and for the control of gut dysbiosis. Medicherla et al. (2015) have
already proved that Ge-OH effectively modulates experimental
colitis, but the possibility of using this molecule as a therapeutic
agent has yet to be demonstrated. Their study did not consider
the chemical characteristics of Ge-OH that require specific
formulations to be administered. They administered Ge-OH
orally diluted in saline, forgetting that Ge-OH is insoluble in
aqueous solutions in which it rapidly tends to separate from the
water.Moreover, once separated fromwater, Ge-OH reaches high
concentrations at which it could irritate the gut mucosa. Since,
this substance rapidly crosses enterocyte monolayers (Heinlein
et al., 2014), its site of action and its impact on the microbiota
should also be evaluated. To determine whether Ge-OH could
become a therapeutic option in humans, we administered Ge-OH
in appropriate oral or enema formulations to dysbiotic mice and
compared its effects with one of the standard therapies currently
used to manage gut inflammation in IBD patients.
MATERIALS AND METHODS
Ge-OH Oral Formulation
Ge-OH oral formulation was optimized for the administration
route chosen and for a possible transition to use in humans as
it has a strong smell and very unpleasant taste. In addition, Ge-
OH is completely water insoluble and could irritate the mucosae
if administered pure. The oral formulation was then optimized
for a slow release of Ge-OH using a patented soy lecithin
incapsulation. Natural Ge-OH (analytical grade,>98% pure) and
soy lecithin were purchased from Prodasynth (Grasse, France).
All the other reagents were purchased from SIGMA-Aldrich (St
Louis, MO, USA). The stable suspension was prepared by Cedax
Srl (Forlì, Italy) by adding Ge-OH (ρ = 0.899 g/cm3; 17%
by weight) to a solution containing sucrose (16%), deionized
water (22%) and soy lecithin (25%), and ethanol (20%) as
preservative (patent PCT WO 201 1/128597). The suspension
was stored at 4◦C and administered by oral gavage to Ge-OH-
treated mice (4, 5, or 18µl of Ge-OH suspension brought to
the final volume of 100µl with Ge-OH-free suspension). A
Ge-OH-free suspension containing sucrose (16%), soya lecithin
(25%), and ethanol (20%) was administered to the control
group.
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Ge-OH Enema Formulation
The Ge-OH formulation for enema administration was prepared
using glycerin to increase the viscosity of the solution and thereby
facilitate both intracolonic injection and colonic retention.
Enema Ge-OH solution was prepared as follows: natural Ge-OH
(4% v/v) was added to a solution containing PBS and glycerol
(30%v/v). An amount of solution corresponding to 120mg kg(−1)
(body weight, die) was freshly prepared and administered by
enema during the acute phase of colitis. A control solution mixed
as previously described but without Ge-OH was also prepared
and administered to the enema control group. Enema treatments
were administered via a 16G venous catheter (diameter 2mm,
length 48mm; BD Bioscience, Buccinasco, Italy) advanced
through the rectum into the colon until the tip was 10mm
proximal to the anus. A venous catheter was applied to a 1ml
syringe and the suspension was gently injected into the rectum.
Animals were sedated using tiletamine 10mg kg(−1) plus xylazine
2.5mg kg(−1) during enema administration.
Hydrocortisone Enema Treatment
Enema administrations were prepared as follows: hydrocortisone
(0.08% w/v, Sigma) was added to a solution containing PBS
and glycerol (30%v/v). An amount of solution corresponding
to 2.5mg kg(−1) (body weight, die) was freshly prepared and
administered by enema during the acute phase of colitis. Enema
treatments were administered via a 16G venous catheter as
previously described.
Animal Treatment
Sixty-four eight-week-old male C57BL/6 mice were purchased
from Charles River Laboratories (Lecco, Italy). Animals were
housed in collective cages with a controlled environment
containing two mice each, at 22± 2◦C and 50% humidity, under
a 12-h light/dark cycle. Mice were allowed to acclimate to these
conditions for at least 7 days before inclusion in experiments and
had free access to food and water throughout the study.
Mice were randomized into eight experimental groups: the
first (I) group called CTRL (n = 8) received only tap water
for 37 days (1–37). Group II called SoySusp-or received only
tap water for 37 days (1–37) and mice were treated with oral
Ge-OH-free suspension for 17 days (days 8–24) to analyze
possible modifications of the microbiota induced by the soy
lecithin suspension in healthy mice. All the groups III–VIII
received tap water for 16 days (1–16), oral administration of 1.5%
(w/v) dextran sulfate sodium (DSS for colitis, TdB Consultancy,
Sweden) for 7 days in tap water (days 17–23), and tap water for
14 days (25–37). DSS was freshly prepared every 7 days and the
average amount of DSS taken was recorded daily. In addition to
DSS, group III, called DSS (n = 8), received the control oral
Ge-OH-free suspension for 17 days (days 8–24), while group IV,
called DSS+Ger30 or (n = 8), received Ge-OH orally [30mg
kg(−1)] for 17 days (days 8–24). Group V, called DSS+Ger120 or
(n = 8), received Ge-OH [120mg kg(−1)] for 17 days (days 8–
24), and group VI (n = 8), called DSS+Ger120 En, received four
enema administrations of Ge-OH on experimental days 19, 21,
23, and 25. Group VII (n = 8), called DSS+Susp enema, received
four enema administrations of glycerol-PBS suspension on days
19, 21, 23, and 25.
The last group, VIII, called DSS+hydrocortisone enema,
received four enema administrations of glycerol-PBS-
hydrocortisone on days 19, 21, 23, and 25. This group was
used as a model to understand how colitis is clinically modulated
by a powerful drug. Hydrocortisone was administered by enema
at doses of 2.5mg kg(−1) body weight.
The experimental design is schematized in Figure 1. The
experiments were carried out in accordance European and Italian
guidelines. They were approved by the Institutional Ethical
Review Board of the University of Bologna and by the Italian
Ministry for Research and were repeated twice.
Disease Activity Index (DAI)
DAI was calculated by the combined score of weight loss, stool
consistency and bleeding, as detailed in Table 1. All parameters
were scored from day 1 to day 37.
Histological Evaluation of Colitis
Mice (n = 2 for each experimental group) were anesthetized
using Zoletil-100 [10mg kg(−1); Virbac, Carros, France], and
FIGURE 1 | Experimental design of the study. Animal treatment and the collection of feces, blood, and tissue are indicated (dark blue) in the grid.
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TABLE 1 | Disease activity index (DAI) score parameters.
Stool consistency Bleeding Weight loss
0 = Formed 0 = Normal color stool 0 = No weight loss
1 = Mild-soft 1 = Brown color 1 = 5–10% weight loss
2 = Very soft 2 = Reddish color 2 = 11–15% weight loss
3 = Watery stool 3 = Bloody stool 3 = 16–20% weight loss
4 = >20% weight loss
Xilor [2.5mg kg(−1); Bio98, Milan, Italy] by intramuscular
injection and sacrificed by cervical dislocation on day 25 (2 days
after the end of DSS treatment, when the maximum DAI score
was reached), and day 37, at the end of weight recovery. The colon
was excised, rinsed with saline solution, fixed in 4% formalin and
embedded in paraffin. Four micrometer sections were stained
with hematoxylin-eosin and observed for histological assessment
of epithelial damage by a pathologist in a blinded manner.
Determination of Plasma Cytokine Levels
Blood samples (200µl) were taken from the tail vein on
days 25 and 37 and collected in Eppendorf tubes. Blood was
centrifuged at 1000 rpm for 10min, and plasma was collected
and stored at −80◦C until BioPlex analysis. Cytokine levels were
determined using a multiplexed mouse bead immunoassay kit
(Bio-Rad, CA, USA). The six-plex assays (IL-1β, IL-6, IL-10, IL-
17A, IFNγ, TNFα) were performed in 96-well plates following
the manufacturer’s instructions. Microsphere magnetic beads
coated with monoclonal antibodies against the different target
analytes were added to the wells. After 30min incubation, the
wells were washed and biotinylated secondary antibodies were
added. After incubation for 30min, beads were washed and then
incubated for 10min with streptavidin-PE conjugated to the
fluorescent protein, phycoerythrin (streptavidin/phycoerythrin).
After washing, the beads (a minimum of 100 per analyte)
were analyzed in the BioPlex 200 instrument (BioRad). Sample
concentrations were estimated from the standard curve using
a fifth-order polynomial equation and expressed as pg/ml after
adjusting for the dilution factor (Bio-Plex Manager software 5.0).
The sensitivities of the assay were 3.14 pg/ml (IL-1β), 1.34 pg/ml
(IL-6), 1.38 pg/ml (IL-10), 2.38 pg/ml (IL-17), 1.38 pg/ml (IFNγ),
and 2.73 pg/ml (TNFα). Samples below the detection limit of the
assay were recorded as zero. The intra-assay CV was<14%.
Characterization of the Intestinal
Microbiota by HTF-Microbi.Array
The intestinal mice microbiota was characterized using the
fully validated diphylogenetic DNA microarray platform HTF-
Microbi.Array. Targeting 33 phylogenetically related groups, this
LDR-based universal array covers up to 95% of the mammalian
gut microbiota. Gut microbiota analysis was performed on
days 18, 25, 29, and 38. Total DNA from fecal material was
extracted using the QIAamp DNA Stool Mini Kit (Qiagen)
according to the modified protocol previously reported (Candela
et al., 2010, 2012). Final DNA concentration was determined
using NanoDrop ND-1000 (NanoDrop Technologies). A nearly
full-length portion of 16S rDNA gene was amplified using
universal forward primer 27F and reverse primer 1492R,
according to the protocol previously described (Castiglioni
et al., 2004) PCR amplifications were performed in a Biometra
Thermal Cycler T Gradient (Biometra, Göttingen, Germany).
PCR products were purified using the High Pure PCR Cleanup
Microkit (Roche, Mannheim, Germany), eluted in 30µl of sterile
water and quantified with NanoDrop ND-1000. Slide chemical
treatment, array production, LDR protocol, and hybridization
conditions were performed as previously reported (Candela
et al., 2012). Briefly, LDR reactions were carried out in a
final volume of 20µl containing 500 fmol of each LDR-UA
HTF-Microbi.Array probe, 50 fmol of PCR product, and 25
fmol of the synthetic template (5′-AGCCGCGAACACCACGAT
CGACCGGCGCGCGCAGCTGCAGCTTGCTCATG-3′). LDR
products were hybridized on universal arrays, setting the probe
annealing temperature at 60◦C. All arrays were scanned and
processed according to the protocol and parameters already
described. Fluorescence intensities were normalized on the
basis of the synthetic ligation control signal. The relative
abundance of each bacterial group was obtained by calculating
the relative fluorescence contribution of the corresponding HTF-
Microbi.Array probe as a percentage of the total fluorescence.
RNA Extraction and Real-Time PCR
Colon specimens were collected immediately after sacrifice
and total RNA was extracted using Trizol R© reagent (Life
Technologies, CA, USA) according to the manufacturer’s
instructions. Extracted RNA samples were treated with
DNase I to remove any genomic DNA contamination using
DNA-free kit (Ambion, USA) and reverse-transcripted using
RevertAidTM First Strand cDNA Synthesis Kit (Fermentas,
Canada). COX-2 and β-actin mRNAs were reverse-transcribed
using random hexamer primers (Fermentas, Canada). COX-2
and β-actin mRNA levels were analyzed by real-time PCR
using SYBR R© Select Master Mix (Life Technologies, CA, USA)
and StepOnePlusTM system (Applied Biosystems, CA, USA)
according to the manufacturers’ instructions. The melting curve
data were collected to check PCR specificity. Each cDNA sample
was analyzed in triplicate. COX-2 mRNA levels were normalized
against β-actin mRNA and relative expressions were calculated
using the 2-21Ct formula. COX-2 primer pair: 5′- TTC TCT
ACA ACA ACT CCA TCC TC -3′ and 5′- GCA GCC ATT TCC
TTC TCT CC -3′ (247 bp product); β-actin primer pair: 5′- ACC
AAC TGG GAC GAC ATG GAG -3′ and 5′- GTG GTG GTG
AAG CTG TAG CC -3′ (380 bp product).
Data Analysis
Statistical analysis was carried out using GraphPad Prism 6
(GraphPad Software Inc., San Diego, CA, USA). Data are
expressed as mean ± SEM of at least three independent
determinations. Student’s t-test, analysis of variance (one-way
ANOVA) followed by Bonferroni’s post-hoc test for multiple
comparison were used to assess the statistical significance of the
differences. Differences were considered statistically significant
at P < 0.05. Euclidean distance of HTF-Microbi.Array relative
abundance profiles were used to perform PCoA and analysis
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was accomplished using the R packages Made4, Vegan, and Stats
(www.cran.org).
RESULTS
Clinical Colitis Activity
The effect of DSS and DSS-Ge-OH treatments was evaluated
considering the DAI calculated as the sum of weight loss,
stool consistency, and blending scores (Table 1). All DSS-treated
mice started to show mild clinical signs of disease 2 days
before the end of the 1.5% DSS treatment (day 21) due to the
simultaneous increase in stool consistency index and bleeding
index (maximum DAI score = 2.3). The most evident clinical
signs of each group were recorded between days 25 and 27
(Figure 2) with a maximum DAI score of 9.1 for the DSS group
and with severe weight loss that peaked between days 25 and
28 (Figure 2A). Ge-OH at 30mg kg(−1) reduced the DAI score
of colitis during the acute phase but did not affect this index
during the recovery phase (Figure 2B). At this Ge-OH dose,
the DAI score maintained the same trend observed in DSS-
treated mice. At the higher oral dose, Ge-OH reduced the DAI
score for almost the entire duration of colitis and especially
during the recovery phase. Statistical analysis of data in Figure 2B
are provided in Supplementary Table 1. These positive Ge-OH
effects were further enhanced when colitic mice were treated
with enema-administered Ge-OH, resulting in a very low weight
loss and a strongly reduced DAI score for the whole duration of
colitis.
Inflammatory Cytokine Profile of Colitis
Plasma levels of IL-1β, IL-6, IL-10, IL-17, TNFα, and IFNγ were
detected in blood samples from all experimental mice group at
two different time points, one corresponding to the acute phase of
colitis (day 25), and one at the end of the recovery phase (day 37).
DSS treatment significantly increased (P < 0.05) all the cytokines
measured, both at day 25 and day 37 (Figure 3). At day 25, oral
administration of Ge-OH at the lower dose of 30 mg/mg kg(−1)
did not modify the inflammatory profile of DSS-treated mice.
Oral administration of the higher Ge-OH dose of 120mg kg(−1)
and Ge-OH 120mg kg(−1) enema administration significantly
decreased IL-10, IL-17, TNFα, and IFNγ ( P < 0.05), but neither
IL-1β nor IL-6. At day 37 when colitis tended to become chronic,
Ge-OH-treated mice showed a better inflammatory profile than
DSS-treated mice. In particular, the lower dose of oral Ge-OH
significantly reduced all the measured cytokines (P < 0.05).
The higher oral dose and enema administration of Ge-OH
significantly decreased IL-1β, IL-17, IFNγ, and TNFα (P < 0.05)
but neither IL-6 nor IL-10.
Histological Evaluation of Colitis
Histological evaluation of the colon was made from the colocecal
junction to the anus. Overall, the tissue damage tended to
be limited to the terminal colon and rectum regions, and
can be classified as moderate colitis (Figure 4). At day 25
(Figures 4A–C), the colon mucosa in the DSS-treated mice
showed a diffuse loss of goblet cells, focal crypt abscesses, diffuse
hyperemia, moderate cellular infiltration in themucosa, and focal
epithelial erosions. Diffuse hyperemia, mild loss of goblet cells,
mild cellular infiltration but no crypt abscesses, or epithelial
erosions were also present in the mucosa of oral Ge-OH-treated
mice at both doses administered [see Supplementary Figure 1 for
Ge-OH 30mg kg(−1)]. The colon in the Ge-OH enema-treated
mice was characterized by a lowermucosa distortion (elongation)
and showed moderate loss of epithelium, and low leukocyte
infiltrations.
After weight recovery (day 37), the colon mucosa in the
DSS-treated mice showed a diffuse loss of goblet cells, focal
crypt abscesses, diffuse hyperemia, and mild cellular infiltration
(Figure 4D), while the mucosa of oral Ge-OH-treated mice
presented diffuse hyperemia but a milder loss of goblet cells,
a milder cellular infiltration, and no crypt abscesses at with
dose administered (Figures 4E,F). Colon mucosa in the enema
Ge-OH-treated mice showed a normal architecture similar to
that of healthy controls. In conclusion, histological and clinical
improvements were evident in the Ge-OH-treated mice and
particularly in the enema-treated animals.
Ge-OH-Induced Microbiota Modifications
Since the Ge-OH-free suspension itself did not inducemicrobiota
alterations, we investigated the impact of Ge-OH treatment on
DSS-induced microbiota dysbiosis in mice. Mice stools were
collected on days 18, 25, 29, and 37. Figure 5 shows the
phylogenetic structure of the intestinal microbiota characterized
using the HTF-Microbi.Array universal platform. DSS treatment
prompted profound, progressive, and transient changes in mice
microbiota composition, compared to colitis-negative controls
(group I), defining a peculiar microbiota trajectory during the
induced colitis. In particular, on day 18, after 1 day of DSS
treatment, the overall microbiota structure of DSS mice still
resembled that of control mice. At day 25, after seven days of DSS,
we observed a global temporary restructuring of the intestinal
microbiota composition. At day 29 a transitory reduction of
Bacteroidetes associated with an increase in Firmicutes was
recorded. However, on day 37, DSS-treated mice recovered a
microbiota structure similar to that of healthy controls.
While oral Ge-OH treatment at 30mg kg(−1) exerted only
a mild impact on the temporal dynamics of DSS-induced
microbiota dysbiosis, oral and enema treatment at a dose of
120mg kg(−1) resulted in considerable protection against the
transient DSS-dependent reduction of Bacteroidetes, favoring a
faster recovery of a community profile similar to that of healthy
controls. In particular, on day 25, Ge-OH at 120mg kg(−1) (both
enema and orally administered) triggered a Lactobacillaceae
increase that reached a relative abundance of 11.2 and 9.7%
respectively, notably higher than the corresponding value in
control mice. This Ge-OH-dependent high relative abundance
of Lactobacillaceae was maintained until day 29 after which Ge-
OH-treated mice permanently recovered from the DSS-induced
reduction of Bacteroidetes 8 days earlier with respect to the
corresponding DSS-treated mice. These effects are certainly
related to the antibacterial action of Ge-OH, evidenced by its
low minimal inhibitory concentration (MIC) on model bacteria
species (see Supplementary Table 2). Differently from what
observed in DSS treated mice, in healthy mice Ge-OH treatment,
Frontiers in Pharmacology | www.frontiersin.org 5 March 2016 | Volume 7 | Article 38
De Fazio et al. Geraniol Treatment of DSS Colitic Mice
FIGURE 2 | Weight change percentage (A) and disease activity index (DAI) score of colitis (B) in different mice experimental groups. Maximum DAI score
was reached between days 25 and 27. Maximum weight loss (22%) was recorded between days 22 and 27. Weight recovery ends at days 37. Data are expressed as
mean ± SD. Analysis of variance (one way-ANOVA) was performed (for weight changes only at days 26, 29, and 32) to assess the statistical significance of the
differences. *P < 0.05 if compared to DSS group mean values. Statistical significance for DAI score differences (analysis of variance, one way-ANOVA) are reported in
Supplementary Table 1.
even at the dose of 120mg kg(−1) (orally administered), did
not produced the same marked changes in the microbiota.
Indeed, the microbiota composition of mice treated with Ge-OH
120mg kg(−1) showed a slight increase in Lactobacillaceae,
Bacillaceae and Bacteroidetes families (see Supplementary
Figure 2).
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FIGURE 3 | Plasma cytokine variations during experimental colitis, measured at days 25 and 37. Cytokines were determined using a 6-plex mouse bead
immunoassay kit. Levels of IL-1β (A), IL-6 (B), IL-10 (C), IL-17A (D), IFN-γ (E), and TNFα (F) are shown. Data are expressed as mean ± SEM of at least three
replicates (n = 9). #P < 0.05 in the comparison between to Ge-OH 30 and Ge-OH 120 or groups. *P < 0.05 if compared to DSS group.
Down-Regulation of COX-2 through Ge-OH
Treatment
Since COX-2 plays a crucial role in the production of many lipid
mediators involved in intestinal inflammation and is one of the
major targets of IBD pharmacological therapy, we analyzed COX-
2 mRNA expression in colon tissues during DSS-induced colitis
(Figure 6). Our data support the previously reported finding
that COX-2 mRNA significantly increases in the gut wall of
DSS-treated mice (De Fazio et al., 2014). At day 25, we observed
a significant increase (1.8-fold, P < 0.05) in COX-2 expression
in the gut wall of DSS-treated mice. Ge-OH decrease the COX-2
expression in DSS treated mice returning it to values comparable
to those of the control.
DISCUSSION
Inflammatory bowel disease (IBD) comprises a group of
chronic inflammatory conditions affecting the gastrointestinal
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FIGURE 4 | Differences in histological architecture induced by Ge-OH 120mg kg(−1) and hydrocortisone 2.5mg kg(−1) during the experimental colitis.
Colon specimens were collected from mice on days 25 (A–D) and 37 (E–H). Histopathological changes in individual crypts are shown in representative hematoxylin
and eosin-stained sections. Red arrows indicate loss of crypt architecture associated with epithelial damage and flattened villi while black arrows indicate leukocyte
infiltration (Magnification: 10X; bar = 100µm).
tract. The mucosal immune system of IBD patients has lost
the ability to self-regulate and remains chronically activated.
IBD is a well-established risk factor for colon cancer (CRC)
development, with an increasing incidence linked to younger
age at IBD diagnosis, longer IBD duration, and more severe
intestinal inflammation. Conventional IBD therapies include
COX-2 inhibitors (aminosalicylates and their derivatives),
corticosteroids, immunomodulatory drugs, antibiotics, and
biologic drugs such as the monoclonal antibody against tumor
necrosis factor alpha (TNFα), a pivotal pro-inflammatory
cytokine able to start and maintain the inflammatory process in
the gut. Besides antibiotics, probiotics have also been used in the
treatment of ulcerative colitis to counteract dysbiosis (Bibiloni
et al., 2005). Since, IBD usually relapses, all these therapies require
long-term administration.
Ge-OH is a non-toxic compound, classified as Generally
Recognized As Safe (GRAS) by the US Food and Drug
Administration. The European Food Security Agency (EFSA)
hazard assessment conclusion for Ge-OH established a Derived
No Effect Level (DNEL) of 13.5mg kg(−1) for humans
(General Population—Hazard via oral route), corresponding
to 100–120mg kg(−1) in mice. Ge-OH is currently receiving
substantial attention for its antitumorigenic, anti-inflammatory,
and antimicrobial effects that have been clearly demonstrated
in vitro. Nevertheless, its role as an anti-dysbiotic agent in colon
inflammation has never been investigated. Our study adopted
a mouse model of DSS-induced moderate to severe colitis to
evaluate the antimicrobial and anti-inflammatory therapeutic
activity of Ge-OH doses considered safe.
Ge-OH, orally administered at 30 and 120mg kg(−1) halved
the mice weight loss and reduced the disease activity index (DAI)
of colitis. At histological level, Ge-OH was able to preserve crypt
architecture and decrease leukocyte infiltration, with a much
more evident effect at the higher dose (both enema or orally
administered). Moreover, enema-administered Ge-OH strongly
improved signs of colitis maintaining a lower DAI and preserving
colon mucosa integrity. These clinical observations are further
supported by a significant reduction of COX-2mRNA expression
in the colonic mucosa of Ge-OH-treated mice.
Circulating cytokine levels are indicative of the overall
inflammatory status of animals, with IL-1, IL-6, IL-17, and TNFα
playing a key role in the pathogenesis of IBD (Muzes et al.,
2012). TNFα is a master cytokine in IBD pathogenesis and its
orchestrating role in colonic inflammation is confirmed by the
efficacy of anti-TNFα therapy in IBD patients (Chaparro et al.,
2012). The circulating TNFα level correlates with clinical activity
both in ulcerative colitis and Crohn’s disease (Bibiloni et al., 2005)
and increases in acute phases of DSS colitis (Alex et al., 2009).
So, while circulating TNFα and IL-17 levels seem to correlate
with the DSS colitis clinical course, IL-1β, and IL-10 mainly
correlate with the histological damage that tends to become
chronic (Alex et al., 2009; De Fazio et al., 2014). The higher oral
dose of Ge-OH significantly reduced circulating TNFα and IL-
17 in Ge-OH-treated mice after weight recovery at the end of
the experiments. This decrease was equally evident after Ge-OH
enema administration. These results are in agreement with those
obtained by Medicherla et al. (2015) who found a significantly
reduced expression of the major pro-inflammatory cytokines
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FIGURE 5 | Temporal dynamics at the family level of the fecal microbial community of dextran sulfate sodium (DSS)-treated mice. The microbiota
composition of healthy mice (CTRL), colitic mice (DSS), colitic geraniol orally treated mice [Ge-OH 30mg kg(−1), 120mg kg(−1)], and colitic geraniol enema-treated
mice [120mg kg(−1)] is shown. Other Bacteriodetes and Firmicutes families that are not are listed separately have been combined into a single group. The microbiota
composition of the mice group treated with Ge-OH-free oral suspension or Ge-OH-free enema suspension showed no differences from those of the healthy mice
group.
in the colon specimens (TNF-α, IL-1β, and IL-6), associated
with reduced total and nuclear amounts of NF-κB (p65) after
oral administration of Ge-OH [50 and 100mg Kg (−1)]. They
also identified an antioxidant activity of Ge-OH at colon level,
evaluated as a decrease in lipid peroxidation marker.
DSS treatment compromises gut microbiota homeostasis,
resulting in a dysbiosis characterized by a transient reduction
of dominant mutualistic microbiota components such as
Bacteroidetes, confirming previous findings (Nagalingam et al.,
2011). Ge-OH oral and enema treatment at 120mg kg(−1)
protects DSS-treated mice against this transient reduction
of Bacteroidetes, boosting a faster recovery of a healthy
microbiota profile. Interestingly, 120mg kg(−1) geraniol-treated
mice presented a transient increase in the relative abundance
of Lactobacillaceae from day 25 to day 29. This raises the
question of whether the transient Ge-OH-dependent increase
in Lactobacillaceae, heralding the recovery of a healthy profile,
is somehow involved in promoting a faster recovery from
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FIGURE 6 | Geraniol (Ge-OH) modulates cyclooxygenase-2 (COX-2)
expression in vivo in colon specimens during the acute phase (day 25).
COX-2 mRNA expression was evaluated by real-time PCR. COX-2 mRNA
levels were normalized against β-actin mRNA and relative expressions were
calculated using the 2-21Ct formula. COX-2 overexpression induced by DSS
was significantly reduced by Ge-OH treatment. Data are expressed as mean ±
SEM of at least three replicates (n = 6). *P < 0.05 compared to DSS group.
#P < 0.05 compared to CTRL group.
DSS-associated dysbiosis. Dysbiosis always includes a decreased
bacterial biodiversity (Honda and Littman, 2012). GeOH 120mg
kg(−1) treatment was able to increase bacterial biodiversity
in DSS-treated mice starting from the 10th day of Ge-OH
assumption. It is likely that the decreased inflammation we
observed in Ge-OH oral and enema-treated mice during colitis
recovery is also due to the healthy microbiota status found in
these mice.
The central finding of this study in a colitis model is the
multi-target effect of Ge-OH treatment that simultaneously
targeted dysbiosis, local, and systemic inflammation andmucosal
damage. The decreased activity of COX-2 in colon specimens
is a clear demonstration of the anti-inflammatory effect of
Ge-OH that contributes to the decreased mucosal damage.
This effect certainly involves the colonic mucosa, even if it is
reasonable to assume that in vivo Ge-OH may also target COX-2
expression in immune system cells inside the colon wall (Su et al.,
2010).
CONCLUSIONS
IBD therapy is based on the use of anti-inflammatory molecules
and immunomodulatory agents that act by strongly and non-
specifically inhibiting the inflammatory response but their long-
term use might trigger the onset of severe side-effects. The
effects of Ge-OH could be of great importance in the treatment
of human IBD. Since geraniol’s antimicrobial effect does not
seem to induce bacterial resistance, a phenomenon commonly
observed with conventional antibiotic drugs, it would be very
interesting to ascertain whether Ge-OH is able to control
dysbiosis and inflammatory status in human IBD patients. In
addition, Ge-OH’s anti-tumor activities could help reduce the
risk of CRC in IBD patients. Thus, this investigation represents
a preclinical assessment prior to developing further studies
on the effects of oral and enema Ge-OH administration in
patients with gut inflammation and/or dysbiosis. Since Ge-
OH has its peak therapeutic effect on colitis when directly
administered into the colon, it is of great importance to find
oral delivery systems able to inhibit intestinal Ge-OH absorption
after its oral administration. On the contrary, Ge-OH without
any delivery system may be orally administered to obtain a
systemic anti-inflammatory effect or to target other organs, such
as brain.
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